D-0974-2017 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0974-2017 was initiated by Lupin Pharmaceuticals Inc. on Jun 22, 2017 and is designated Class III. Reason for recall: Failed Dissolution Specifications: out of specification observed in dissolution testing at 3 month long term stability study. The recall status is terminated (terminated Jan 17, 2019). Affected quantity: 12480 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 19, 2017
Initiation Date
Jun 22, 2017
Termination Date
Jan 17, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12480 bottles

Product description

Paroxetine Extended-Release Tablets USP, 12.5 mg, 30 count bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland, 21202, Manufactured by: Lupin Limited, Pithampur (M.P.) 454 775, India, NDC: 68180-647-06

Reason for recall

Failed Dissolution Specifications: out of specification observed in dissolution testing at 3 month long term stability study.

Distribution pattern

Nationwide in the USA

Code information

Lots: H605712, H605711, H605710, EXP November 2018; H702255, H702202 EXP March 2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0974-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0974-2017. Report a data issue: hello@regdatalab.com.